NanoRepro AGHAM:NN6 -2.12%51 EV-to-FCF is 11.46 as of Jul. 09, 2026. GuruFocus rates HAM:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.05 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 77.55% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, NanoRepro AG's Enterprise Value is €20.46 Mil.
NanoRepro AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was €1.79 Mil. Therefore, NanoRepro AG's EV-to-FCF for today is 11.46.
The historical rank and industry rank for NanoRepro AG's EV-to-FCF or its related term are showing as below:
HAM:NN6'
s EV-to-FCF Range Over the Past 10 Years
Min: -144.44 Med: -4.68 Max: 11.46
Current: 11.46
During the past 13 years, the highest EV-to-FCF of NanoRepro AG was 11.46. The lowest was -144.44. And the median was -4.68.
HAM:NN6's EV-to-FCF is ranked better than 77.55% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.465
vs HAM:NN6: 11.46
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NanoRepro AG's PE Ratio (TTM) for today is calculated as:
NanoRepro AG's share price for today is €2.31.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NanoRepro AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2025 was €-0.137.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
NanoRepro AG EV-to-FCF Related Terms
NanoRepro AG EV-to-FCF Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, NanoRepro AG's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's EV-to-FCF falls into.
NanoRepro AG's current Enterprise Value is €20.46 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NanoRepro AG's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2025 was €1.79 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NanoRepro AG (HAM:NN6) has a EV-to-FCF of 11.46 as of Jul. 09, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NanoRepro AG and its competitors. According to the industry distribution chart, NanoRepro AG ranks #22 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 22.4%.
Is NanoRepro AG's EV-to-FCF too high?
NanoRepro AG's current EV-to-FCF is 11.46. The Medical Diagnostics & Research industry median EV-to-FCF is 22.47. NanoRepro AG's value of 11.46 is 49% below this industry median. Based on the distribution chart, NanoRepro AG ranks #22 out of 98 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #22 out of 98 companies for EV-to-FCF. This places NanoRepro AG in the top 22% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 22.47. NanoRepro AG's value of 11.46 is 49% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.47, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current EV-to-FCF of 11.46 is 49% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current EV-to-FCF is 11.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (HAM:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.05, compared to a current price of €2.31 — trading 120% above its estimated fair value. The current EV-to-FCF is 11.46 and 49% below the Medical Diagnostics & Research industry median of 22.47. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For NanoRepro AG (HAM:NN6), the current EV-to-FCF is 11.46 as of Jul. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (HAM:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €2.31 is trading 120% above its estimated GF Value™ of €1.05.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for HAM:NN6:
EV-to-FCF: 11.46
GF Value™: €1.05 vs. price of €2.31 (120% above fair value)
Industry Position: 49% below the Medical Diagnostics & Research median (#22 of 98)
No single metric tells the full story. See the HAM:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for HAM:NN6
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:NN6 has been successfully added to your 
